Up-to-date molecular medicine strategies for management of ocular surface neovascularization.
Adv Drug Deliv Rev
; 201: 115084, 2023 10.
Article
en En
| MEDLINE
| ID: mdl-37689278
ABSTRACT
Ocular surface neovascularization and its resulting pathological changes significantly alter corneal refraction and obstruct the light path to the retina, and hence is a major cause of vision loss. Various factors such as infection, irritation, trauma, dry eye, and ocular surface surgery trigger neovascularization via angiogenesis and lymphangiogenesis dependent on VEGF-related and alternative mechanisms. Recent advances in antiangiogenic drugs, nanotechnology, gene therapy, surgical equipment and techniques, animal models, and drug delivery strategies have provided a range of novel therapeutic options for the treatment of ocular surface neovascularization. In this review article, we comprehensively discuss the etiology and mechanisms of corneal neovascularization and other types of ocular surface neovascularization, as well as emerging animal models and drug delivery strategies that facilitate its management.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Neovascularización de la Córnea
/
Medicina Molecular
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
Adv Drug Deliv Rev
Asunto de la revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Año:
2023
Tipo del documento:
Article